For research teamsHelp me find a study
Back to all studies
CompletedNCT00337285

NRP104 30 mg, 50 mg, or 70 mg Per Day for ADHD

This study is completed in the United States. It is testing NRP104 30 mg, 50 mg, or 70 mg Per Day for ADHD.

ADHD, Attention Deficit Disorders With HyperactivityDrugFrom 18 Years to 55 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore recruiting studies on this topic

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether NRP104 may be useful for adults experiencing ADHD.

What would participation involve?

Participants may receive NRP104, attend study visits with the research team. The registry lists locations in the United States.

Who is it mainly for?

This study appears to be mainly for adults with ADHD.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)

  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateJuly 2006
Recruitment status
Completed
Enrollment listed in the registry
349
Sponsor
New River Pharmaceuticals
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 55 Years
Official registry ID
NCT00337285
Official title
A Long-Term, Open-Label, and Single-Arm Study of NRP104 30 mg, 50 mg, or 70 mg Per Day in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT00337285. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

United States · 45 sites
  • Clinical Study Centers, LLC
    Little Rock, Arkansas
    Site status: Not listed — confirm with the team
  • Valley Clinical Research, Inc.
    El Centro, California
    Site status: Not listed — confirm with the team
  • University of California, Irvine Child Development Center
    Irvine, California
    Site status: Not listed — confirm with the team
  • Bay Area Research Institute
    Lafayette, California
    Site status: Not listed — confirm with the team
  • Peninsula Research Associates
    Rolling Hills Estate, California
    Site status: Not listed — confirm with the team
  • University of California, San Francisco, Dept. of Psychiatry
    San Francisco, California
    Site status: Not listed — confirm with the team
  • Encompass Clinical Research
    Spring Valley, California
    Site status: Not listed — confirm with the team
  • Alpine Clinical Research Center
    Boulder, Colorado
    Site status: Not listed — confirm with the team
  • Psychiatric Medicine Center
    New London, Connecticut
    Site status: Not listed — confirm with the team
  • Gulfcoast Clinical Research Center
    Fort Myers, Florida
    Site status: Not listed — confirm with the team
  • Miami Research Associates
    Miami, Florida
    Site status: Not listed — confirm with the team
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida
    Site status: Not listed — confirm with the team
  • Meridien Research
    Tampa, Florida
    Site status: Not listed — confirm with the team
  • Janus Center for Psychiatric Research LLC
    West Palm Beach, Florida
    Site status: Not listed — confirm with the team
  • Northwest Behavioral Research Center
    Roswell, Georgia
    Site status: Not listed — confirm with the team
  • Carman Research
    Smyrna, Georgia
    Site status: Not listed — confirm with the team
  • Psychiatric Associates
    Overland Park, Kansas
    Site status: Not listed — confirm with the team
  • Vince and Associates Clinical Research
    Overland Park, Kansas
    Site status: Not listed — confirm with the team
  • Johns Hopkins at Green Spring Station
    Lutherville, Maryland
    Site status: Not listed — confirm with the team
  • Marc Hertzman, MD
    Rockville, Maryland
    Site status: Not listed — confirm with the team
  • Masschusetts General Hospital
    Cambridge, Massachusetts
    Site status: Not listed — confirm with the team
  • Summit Research Network (Michigan) Inc.
    Flint, Michigan
    Site status: Not listed — confirm with the team
  • Rochester Center for Behavioral Medicine
    Rochester Hills, Michigan
    Site status: Not listed — confirm with the team
  • St Charles Psychiatric Associates-Midwest Research
    Saint Charles, Missouri
    Site status: Not listed — confirm with the team
  • Center for Psychiatry and Behavioral Medicine
    Las Vegas, Nevada
    Site status: Not listed — confirm with the team
  • CNS Research Institute (CRI)
    Clementon, New Jersey
    Site status: Not listed — confirm with the team
  • VA New York Harbor Healthcare System
    New York, New York
    Site status: Not listed — confirm with the team
  • Duke University ADHD Program
    Durham, North Carolina
    Site status: Not listed — confirm with the team
  • Richard Weisler and Associates
    Raleigh, North Carolina
    Site status: Not listed — confirm with the team
  • The Ohio State University
    Columbus, Ohio
    Site status: Not listed — confirm with the team
  • IPS Research Company
    Oklahoma City, Oklahoma
    Site status: Not listed — confirm with the team
  • Oregon Center for Clinical Investigations, Inc.
    Portland, Oregon
    Site status: Not listed — confirm with the team
  • CNS Research Institute, P.C.
    Philadelphia, Pennsylvania
    Site status: Not listed — confirm with the team
  • FutureSearch Trials
    Austin, Texas
    Site status: Not listed — confirm with the team
  • Claghorn-Lesem Research Clinic
    Bellaire, Texas
    Site status: Not listed — confirm with the team
  • Bayou City Research
    Houston, Texas
    Site status: Not listed — confirm with the team
  • Red Oak Psychiatry Associates, P.A.
    Houston, Texas
    Site status: Not listed — confirm with the team
  • R/D Clinical Research, Inc.
    Lake Jackson, Texas
    Site status: Not listed — confirm with the team
  • John M. Turnbow, MD, PA
    Lubbock, Texas
    Site status: Not listed — confirm with the team
  • The Clinical Study Center
    Burlington, Vermont
    Site status: Not listed — confirm with the team
  • Neuropsychiatric Associates
    Woodstock, Vermont
    Site status: Not listed — confirm with the team
  • Psychiatric Alliance of the Blue Ridge Clinical Research
    Charlottesville, Virginia
    Site status: Not listed — confirm with the team
  • NeuroScience, Inc.
    Herndon, Virginia
    Site status: Not listed — confirm with the team
  • Brighton Research Group
    Virginia Beach, Virginia
    Site status: Not listed — confirm with the team
  • Summit Research Network LLC (Seattle)
    Seattle, Washington
    Site status: Not listed — confirm with the team
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with adhd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Vyvanse (lisdexamfetamine dimesylate), NRP104. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.

Who might this study be for?

This study may concern people with adhd; age range: From 18 Years to 55 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by New River Pharmaceuticals, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.